Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

270.04 +0.66 (+0.24%)
Streaming Delayed Price Updated: 1:03 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 577,771
Open 265.72
Bid (Size) 269.96 (4)
Ask (Size) 270.11 (1)
Prev. Close 269.38
Today's Range 265.72 - 271.68
52wk Range 211.71 - 329.72
Shares Outstanding N/A
Dividend Yield 3.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus... 
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool

Performance

YTD
-9.20%
-9.20%
1 Month
-4.16%
-4.16%
3 Month
-12.96%
-12.96%
6 Month
+0.12%
+0.12%
1 Year
+13.08%
+13.08%

More News

Read More
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
How Is The Market Feeling About Amgen?
Via Benzinga
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Via InvestorPlace
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Is Amgen Stock a Buy?
Via The Motley Fool
7 Analysts Have This To Say About Amgen
Via Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
Via InvestorPlace
Topics Stocks
Exposures US Equities
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Via InvestorPlace
Amgen, Shell And More On CNBC's 'Final Trades'
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Via InvestorPlace
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
Via InvestorPlace
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
2 Biotech Stocks to Buy Hand Over Fist in April
Via The Motley Fool
3 Stocks to Consider Adding to Your Retirement Portfolio in April
Via The Motley Fool
Topics Retirement
Exposures Pension
Is Amgen The Rare Biotech With A Safe Dividend?
Via Talk Markets
Biotech Sector Nears Breakout: Will it Outperform in Q2?
Via MarketBeat
Topics ETFs
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.